



May 2, 2011

For Immediate Release

Company name Otsuka Holdings Co., Ltd.
 Representative Tatsuo Higuchi
 President and Representative Director, CEO
 Code number 4578 First Section , Tokyo Stock Exchange
 Inquiries Takuma Kimura
 Director, Investors Relations Department

Otsuka announces 2011 first quarter U.S. net sales figures of ABILIFY®

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces 2011 first quarter U.S. net sales figures of ABILIFY (aripiprazole), the antipsychotic agent marketed worldwide by its wholly owned direct subsidiary Otsuka Pharmaceutical Co., Ltd. (“Otsuka Pharmaceutical”). The results follow Bristol-Myers Squibb Company’s (“Bristol-Myers Squibb”) results announcement for the first quarter on Thursday, April 28, 2011.

ABILIFY is co-promoted in the U.S. by Otsuka America Pharmaceutical, Inc. (“OAPI,” a wholly owned subsidiary of Otsuka Pharmaceutical) and Bristol-Myers Squibb. Net sales of ABILIFY is reported to OAPI; Otsuka Pharmaceutical pays BMS a fee based on the collaboration agreement. 2011 first quarter U.S. net sales*¹ of ABILIFY reported to OAPI is \$897 millions.

*¹ Net sales in U.S. and Puerto Rico

【OAPI U.S. Net Sales Figure of ABILIFY】

(\$ in millions)	1 st Qtr	2 nd Qtr	3 rd Qtr	4 th Qtr	Year
2011	897*	-	-	-	-
% change	6.4%	-	-	-	-
2010	843	880	831	959	3,512
% change	13.3%	6.0%	0.0%	6.9%	6.3%

* unaudited

About ABILIFY:

Discovered by Otsuka Pharmaceutical Co., Ltd. and jointly developed and commercialized by Otsuka and Bristol-Myers Squibb, ABILIFY is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.

To date, ABILIFY is sold in 65 countries and regions worldwide including Japan with global sales of approximately 370 billion yen in fiscal 2009 accounting for 34.5% of Otsuka Holding’s consolidated results.

About Otsuka Group:

The Otsuka Group is a global organization of 145 healthcare companies with nearly 39,000 employees. Otsuka Holdings Co., Ltd., is the Group’s pure holding company. The main operating companies are Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Otsuka Warehouse Co., Ltd., and Otsuka Chemical Co., Ltd. The Group operates in 23 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and others.

Otsuka-people creating new products for better health worldwide